FOLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amicus Therapeutics Inc (FOLD) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks clear positive momentum, has mixed financial performance, and no significant catalysts to drive immediate growth. It is better to hold off on investing until stronger signals or catalysts emerge.
The stock's MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 44.111, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are close to the current price, suggesting limited immediate upside potential. Historical candlestick analysis shows a high probability of short-term declines (-0.33% next day, -1.44% next week, -6.38% next month).
The company is focused on rare disease therapies, with potential for combined sales of over $1B by 2028 for Galafold and PomOp. Moving averages are bullish, indicating some long-term support.
The company does not expect additional takeover bids, which may limit upside potential. Recent financials show declining net income (-88.53% YoY) and EPS (-80% YoY), despite revenue growth. The stock has a high chance of short-term declines based on historical patterns.
In Q4 2025, revenue increased by 23.72% YoY to $185.2M, but net income dropped by 88.53% YoY to $1.69M. EPS fell by 80% YoY to $0.01, and gross margin declined by 4.61% YoY to 84.64%. While revenue growth is strong, profitability metrics are weakening.
Jefferies downgraded the stock to Hold with a price target of $14.50, citing limited takeover prospects. Citi initiated coverage with a Buy rating and a $17 price target, emphasizing long-term growth potential in rare disease therapies.
